← Back to Search

Dietary Supplement

Vitamin K2/D for Coronavirus

Phase 3
Waitlist Available
Led By Dugald Seely, ND, MSc
Research Sponsored by The Canadian College of Naturopathic Medicine
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline plus weeks 1, 2, 3, 4, 8, and 12
Awards & highlights

Study Summary

This study is evaluating whether a combination of vitamins and minerals might help people with COVID-19.

Eligible Conditions
  • Coronavirus

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline plus weeks 1, 2, 3, 4, 8, and 12
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline plus weeks 1, 2, 3, 4, 8, and 12 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Participant-reported overall health
Secondary outcome measures
All-cause mortality
Effect of COVID-19 on the health status of participants
Frequency of Hospitalizations
+4 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: TreatmentExperimental Treatment3 Interventions
Specific Product: Vitamin D3 50,000 IU Formulation: Capsule. Each capsule will contain 500 mg (50,000 units) cholecalciferol (vitamin D3) Dose: One capsule on day 1 of the intervention period Specific Product: Vitamin K2/D Formulation: Liquid. Each 0.0285 mL drop contains 30 mcg menaquinone-7 (MK-7, vitamin K2) and 3.125 mcg (125 units) cholecalciferol (vitamin D3). Dose: 0.114 mL (four drops) twice daily for 21 days totalling 240mcg MK-7 and 1,000 units cholecalciferol per day. Specific Product: Vitamin C/Zinc Formulation: Capsule. Each capsule will contain 666 mg ascorbic acid (vitamin C) and 8.3 mg of zinc acetate Dose: Three capsules three times daily for 21 days totalling 6 g ascorbic acid and 75 mg zinc acetate per day.
Group II: ControlPlacebo Group2 Interventions
Specific Product: Vitamin D3 50,000 IU Placebo Equivalent: microcrystalline cellulose capsule, 350 mg Specific Product: Vitamin K2/D Placebo Equivalent: Medium chain triglyceride oil Specific Product: Vitamin C/Zinc Placebo Equivalent: microcrystalline cellulose capsule, 350 mg
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Vitamin D3 50,000 IU
2012
N/A
~460

Find a Location

Who is running the clinical trial?

The Canadian College of Naturopathic MedicineLead Sponsor
22 Previous Clinical Trials
2,547 Total Patients Enrolled
Ottawa Hospital Research InstituteOTHER
561 Previous Clinical Trials
2,785,404 Total Patients Enrolled
Vitazan ProfessionalUNKNOWN

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Dietary Supplements for COVID-19
2021. "Dietary Supplements for COVID-19". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04780061.
~24 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top